SI3305813T1 - Protitelesa, specifična za klavdin (CLDN6) - Google Patents

Protitelesa, specifična za klavdin (CLDN6)

Info

Publication number
SI3305813T1
SI3305813T1 SI201031999T SI201031999T SI3305813T1 SI 3305813 T1 SI3305813 T1 SI 3305813T1 SI 201031999 T SI201031999 T SI 201031999T SI 201031999 T SI201031999 T SI 201031999T SI 3305813 T1 SI3305813 T1 SI 3305813T1
Authority
SI
Slovenia
Prior art keywords
cldn6
claudin
antibodies specific
antibodies
specific
Prior art date
Application number
SI201031999T
Other languages
English (en)
Slovenian (sl)
Inventor
Ugur Sahin
Ozlem Tureci
Michael Koslowski
Korden Walter
Stefan Woll
Maria Kreuzberg
Bernd Hubner
Michael Erdeljan
Original Assignee
Astellas Pharma Inc.
TRON - Translationale Onkologie an der Universitaetsmedizin der Johannes Gutenberg - Universitaet Mainz gemeinnuetzige GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP09014136A external-priority patent/EP2322555A1/en
Application filed by Astellas Pharma Inc., TRON - Translationale Onkologie an der Universitaetsmedizin der Johannes Gutenberg - Universitaet Mainz gemeinnuetzige GmbH filed Critical Astellas Pharma Inc.
Publication of SI3305813T1 publication Critical patent/SI3305813T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
SI201031999T 2009-11-11 2010-11-11 Protitelesa, specifična za klavdin (CLDN6) SI3305813T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26020209P 2009-11-11 2009-11-11
EP09014136A EP2322555A1 (en) 2009-11-11 2009-11-11 Antibodies specific for claudin 6 (CLDN6)
US36161810P 2010-07-06 2010-07-06
EP10006956 2010-07-06
EP17189247.4A EP3305813B1 (en) 2009-11-11 2010-11-11 Antibodies specific for claudin 6 (cldn6)

Publications (1)

Publication Number Publication Date
SI3305813T1 true SI3305813T1 (sl) 2020-07-31

Family

ID=43480734

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201031568T SI2499161T1 (sl) 2009-11-11 2010-11-11 Protitelesa, specifična za klaudin 6 (CLDN)
SI201031999T SI3305813T1 (sl) 2009-11-11 2010-11-11 Protitelesa, specifična za klavdin (CLDN6)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI201031568T SI2499161T1 (sl) 2009-11-11 2010-11-11 Protitelesa, specifična za klaudin 6 (CLDN)

Country Status (29)

Country Link
US (5) US9487584B2 (OSRAM)
EP (4) EP2499161B8 (OSRAM)
JP (3) JP5889196B2 (OSRAM)
KR (4) KR101960509B1 (OSRAM)
CN (4) CN106432500B (OSRAM)
AU (3) AU2010318316B2 (OSRAM)
BR (1) BR112012011143B1 (OSRAM)
CA (2) CA3050655A1 (OSRAM)
CY (2) CY1120300T1 (OSRAM)
DK (2) DK2499161T3 (OSRAM)
ES (3) ES2988907T3 (OSRAM)
HR (2) HRP20171749T1 (OSRAM)
HU (2) HUE049404T2 (OSRAM)
IL (2) IL218628B (OSRAM)
LT (2) LT3305813T (OSRAM)
ME (1) ME02943B (OSRAM)
MX (3) MX385874B (OSRAM)
NO (1) NO2499161T3 (OSRAM)
NZ (2) NZ716587A (OSRAM)
PL (3) PL2499161T3 (OSRAM)
PT (2) PT3305813T (OSRAM)
RS (2) RS56502B1 (OSRAM)
RU (1) RU2675997C2 (OSRAM)
SG (2) SG10202110692WA (OSRAM)
SI (2) SI2499161T1 (OSRAM)
SM (1) SMT201700566T1 (OSRAM)
UA (2) UA117799C2 (OSRAM)
WO (1) WO2011057788A1 (OSRAM)
ZA (1) ZA201202418B (OSRAM)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6358588A (ja) * 1986-08-29 1988-03-14 Toshiba Corp バ−コ−ド読取装置
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US12492253B1 (en) * 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
CA2750985C (en) 2009-02-20 2022-07-19 Ganymed Pharmaceuticals Ag Methods and compositions for diagnosis and treatment of cancer
NZ716587A (en) 2009-11-11 2017-10-27 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (cldn6)
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
MX349057B (es) 2010-11-30 2017-07-07 Chugai Pharmaceutical Co Ltd Agente terapeutico que induce citotoxicidad.
NZ724296A (en) * 2011-05-13 2020-05-29 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6
TR201821021T4 (tr) * 2011-05-13 2019-01-21 Ganymed Pharmaceuticals Gmbh Kanser tedavi̇si̇ne yöneli̇k claudin 6 ekspresyonlu anti̇korlar.
CN103320381B (zh) * 2012-03-23 2015-04-15 上海市儿童医院 一种多能干细胞表面标志物及其用途
KR101935088B1 (ko) 2012-08-24 2019-01-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
EP2920209B1 (en) * 2012-11-13 2020-08-05 BioNTech SE Agents for treatment of claudin expressing cancer diseases
HK1209434A1 (en) * 2012-11-13 2016-04-01 Astellas Pharma Inc. Agents for treatment of claudin expressing cancer diseases
PL3027208T3 (pl) * 2013-07-31 2020-11-02 BioNTech SE Diagnoza i terapia nowotworu z udziałem nowotworowych komórek macierzystych
WO2015014376A1 (en) * 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
US10053511B2 (en) * 2013-11-06 2018-08-21 Abbvie Stemcentrx Llc Anti-claudin antibodies and methods of use
EP3070168B1 (en) 2013-11-11 2024-07-31 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified antibody variable region
DK3126381T4 (da) 2014-04-01 2022-04-04 Biontech Cell&Gene Therapies Gmbh Claudin-6-specifikke immunoreceptorer og t-celleepitoper
MA40921A (fr) * 2014-11-05 2017-09-12 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
WO2016076345A1 (ja) 2014-11-11 2016-05-19 中外製薬株式会社 改変された抗体可変領域を含む抗原結合分子のライブラリ
IL299099B2 (en) 2016-06-27 2025-07-01 Univ California Cancer treatment combinations
JP6900051B2 (ja) * 2016-12-07 2021-07-07 国立大学法人大阪大学 Ｃｌａｕｄｉｎ ５抗体、及びその抗体を含有する医薬
CN110612310B (zh) * 2017-05-08 2023-06-27 国立大学法人大阪大学 抗cldn-5抗体及含有该抗体的药物
WO2019048040A1 (en) * 2017-09-06 2019-03-14 Ganymed Pharmaceuticals Gmbh ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER
CN117003875A (zh) 2017-09-29 2023-11-07 第一三共株式会社 抗体或其功能性片段、多核苷酸、表达载体、宿主细胞、糖链重构抗体、药物组合物、应用
US11952422B2 (en) 2017-12-05 2024-04-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137
JP2021510064A (ja) * 2018-01-05 2021-04-15 中外製薬株式会社 細胞傷害誘導治療剤
US12493039B2 (en) 2018-10-09 2025-12-09 Fukushima Medical University Biomarker for predicting the prognosis for an endometrial cancer patient
AU2020223293A1 (en) 2019-02-15 2021-08-19 Integral Molecular, Inc. Claudin 6 antibodies and uses thereof
SI3941946T1 (sl) 2019-03-20 2025-09-30 The Regents Of The University Of California Protitelesa proti klavdinu-6 in konjugati zdravil
TWI856078B (zh) 2019-03-25 2024-09-21 日商第一三共股份有限公司 抗體–吡咯并苯二氮呯衍生物結合物、其製造方法及其用途
MX2022000111A (es) 2019-07-10 2022-02-10 Chugai Pharmaceutical Co Ltd Moleculas de union a claudina-6 y usos de las mismas.
CN111087465B (zh) * 2019-12-24 2020-12-08 广州医科大学 一种针对密蛋白6的抗体偶联药物及应用
CR20220540A (es) 2020-03-31 2022-12-07 Chugai Pharmaceutical Co Ltd Moléculas de union al antígeno multiespecíficas dirigidas a claudina-6 y sus usos
WO2022183502A1 (zh) * 2021-03-05 2022-09-09 上海吉倍生物技术有限公司 抗cldn6抗体及其用途
WO2022192403A1 (en) * 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
WO2023053282A1 (ja) 2021-09-29 2023-04-06 中外製薬株式会社 がんの治療に用いるための細胞傷害誘導治療剤
KR20250046264A (ko) * 2022-07-29 2025-04-02 레전드 바이오테크 아일랜드 리미티드 클라우딘6 겹합 모이어티 및 이의 용도
AR130904A1 (es) 2022-10-31 2025-01-29 Astellas Pharma Inc Conjugado de anticuerpo-fármaco que contiene un compuesto agonista dual del receptor tipo toll 7/8
KR20250114330A (ko) 2022-11-30 2025-07-29 인테그럴 몰큘러 인코포레이티드 클라우딘 6을 표적하는 항체 및 이의 이중특이적 형식
CN116064622B (zh) * 2023-02-13 2023-10-13 优睿赛思(武汉)生物科技有限公司 Claudin6-mCherry报告基因CHO-K1稳转细胞株制备及应用
CN121219323A (zh) * 2023-05-12 2025-12-26 智泽童康(广州)生物科技有限公司 抗cldn6抗体及其用途
US12403202B2 (en) 2023-05-25 2025-09-02 The Regents Of The University Of California Dosage of claudin-6 conjugates for cancer treatment
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
CN119371534B (zh) * 2024-08-21 2025-05-27 百吉生物医药(广州)股份有限公司 一种紧密连接蛋白抗体e02及其应用
CN118754987B (zh) * 2024-08-21 2025-02-11 广州百吉生物制药有限公司 一种紧密连接蛋白抗体h04及其应用
CN119320451B (zh) * 2024-08-21 2025-05-16 百吉生物医药(广州)股份有限公司 一种紧密连接蛋白抗体d03及其应用

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US5830755A (en) 1995-03-27 1998-11-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services T-cell receptors and their use in therapeutic and diagnostic methods
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO2000012708A2 (en) 1998-09-01 2000-03-09 Genentech, Inc. Further pro polypeptides and sequences thereof
US5928631A (en) 1997-06-09 1999-07-27 The Procter & Gamble Company Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins
US20020127584A1 (en) 1997-09-18 2002-09-12 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US5932445A (en) 1997-11-07 1999-08-03 Incyte Pharmaceuticals, Inc. Signal peptide-containing proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
AU773028B2 (en) 1998-11-03 2004-05-13 Adherex Technologies Inc. Compounds and methods for modulating claudin-mediated functions
JP2002532083A (ja) 1998-12-17 2002-10-02 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４７個のヒト分泌タンパク質
WO2000050588A2 (en) 1999-02-22 2000-08-31 Incyte Pharmaceuticals, Inc. Genes associated with diseases of the colon
PT1185648E (pt) 1999-06-22 2007-06-29 Genentech Inc Métodos e composições para a inibição do crescimento de células neoplásicas.
AU2883700A (en) 1999-06-23 2001-01-09 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1514933A1 (en) 1999-07-08 2005-03-16 Research Association for Biotechnology Secretory protein or membrane protein
KR20020027490A (ko) * 1999-07-12 2002-04-13 제넨테크, 인크. Ｃｄ20에 결합하는 길항제를 사용한 외래 항원에 대한면역 반응 차단 방법
EP1242443A4 (en) 1999-12-23 2005-06-22 Nuvelo Inc NEW NUCLEIC ACIDS AND POLYPEPTIDES
WO2001051513A2 (en) 2000-01-14 2001-07-19 Corixa Corporation Ovarian tumor-associated sequences
DK2796553T3 (da) 2000-03-30 2019-09-30 Whitehead Inst Biomedical Res Rna-sekvensspecifikke formidlere af rna-interferens
AU6531101A (en) 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1309620A2 (en) 2000-06-23 2003-05-14 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
JP2004516013A (ja) 2000-07-20 2004-06-03 ジェネンテック・インコーポレーテッド 血管形成に関連する障害を診断及び治療するための組成物と方法
EP1354040A2 (en) 2000-07-20 2003-10-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EA007958B1 (ru) 2000-08-03 2007-02-27 Терапеутик Хьюман Поликлоналз Инк. ТРАНСГЕННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ГУМАНИЗИРОВАННЫЙ ЛОКУС Ig, И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПОЛУЧЕНИЯ ТРАНСГЕННЫХ ЖИВОТНЫХ
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
JP2005500034A (ja) * 2001-06-20 2005-01-06 プロション バイオテク リミテッド 受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用
EP2000148A1 (en) 2001-06-20 2008-12-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of prostate cancer
CA2379661A1 (en) * 2002-03-28 2003-09-28 Kursad Turksen Paracellular drug delivery system
KR20040101502A (ko) 2002-04-16 2004-12-02 제넨테크, 인크. 종양의 진단 및 치료 방법 및 이를 위한 조성물
JP2006516089A (ja) 2002-10-02 2006-06-22 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
ES2744275T3 (es) 2002-10-17 2020-02-24 Genmab As Anticuerpos monoclonales humanos contra CD20 para su uso en el tratamiento de esclerosis múltiple
EP1578996A4 (en) 2002-10-18 2007-12-19 Genentech Inc COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING TUMORS
AT500651B9 (de) 2003-05-27 2010-04-15 Altropus Gmbh Aktiv immunisierender antikörper
KR20060031809A (ko) 2003-06-09 2006-04-13 더 리젠츠 오브 더 유니버시티 오브 미시간 암 치료 및 진단용 조성물 및 방법
US20080305493A1 (en) 2004-03-08 2008-12-11 Avalon Pharmaceuticals Determining Cancer-Linked Genes and Therapeutic Targets Using Molecular Cytogenetic Methods
US7431927B2 (en) * 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
ITRM20050297A1 (it) * 2005-06-08 2006-12-09 Univ Siena Anticorpi diretti contro la proteina basica della mielina che riconoscono un epitopo del cd64 e uso di essi come immunodepressivi.
EP2500352A1 (en) 2005-08-19 2012-09-19 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
SG10201608268RA (en) * 2006-10-02 2016-11-29 Medarex Llc Human antibodies that bind cxcr4 and uses thereof
CN101535471B (zh) * 2006-11-13 2011-06-29 霍夫曼-拉罗奇有限公司 修饰癌症病的抗体180706-02
WO2008114733A1 (ja) 2007-03-16 2008-09-25 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-4抗体
EP1997832A1 (en) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
WO2009025759A1 (en) * 2007-08-17 2009-02-26 Progenics Pharmaceuticals (Nevada), Inc. Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof
WO2009028663A1 (ja) 2007-08-30 2009-03-05 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-3抗体
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
SG187457A1 (en) * 2008-01-11 2013-02-28 Univ Tokyo Anti-cldn6 antibody
US20090258096A1 (en) 2008-04-11 2009-10-15 Bionovo, Inc. Anticancer Methods Employing Extracts of Gleditsia sinensis Lam
EP2352764B1 (en) 2008-10-14 2018-03-28 Ablynx N.V. AMINO ACID SEQUENCES TARGETING HUMAN CD4 and CXCR4, CCR5, TLR4, ALPHAV INTEGRIN, BETA3-INTEGRIN,BETA1-INTEGRIN, HUMAN ALPHA2-INTEGRIN, CD81, SR-BI, CLAUDIN-1, CLAUDIN-6 AND/OR CLAUDIN-9, RESPECTIVELY, AND NEUTRALIZING VIRAL ENTRY
DE102009026973A1 (de) 2008-12-18 2010-07-01 Robert Bosch Gmbh Bremsanlage für ein Kraftfahrzeug und Verfahren zu ihrer Steuerung
EP2221063A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
CA2750985C (en) 2009-02-20 2022-07-19 Ganymed Pharmaceuticals Ag Methods and compositions for diagnosis and treatment of cancer
EP2322555A1 (en) 2009-11-11 2011-05-18 Ganymed Pharmaceuticals AG Antibodies specific for claudin 6 (CLDN6)
NZ716587A (en) * 2009-11-11 2017-10-27 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (cldn6)
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
NZ724296A (en) 2011-05-13 2020-05-29 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6
EP2605017A1 (de) 2011-12-16 2013-06-19 Protagen AG Markersequenzen für gynäkologisches Malignom und deren Verwendung
WO2014015148A1 (en) 2012-07-19 2014-01-23 Amgen Inc. Human btnl3 proteins, nucleic acids, and antibodies and uses thereof
HK1209434A1 (en) * 2012-11-13 2016-04-01 Astellas Pharma Inc. Agents for treatment of claudin expressing cancer diseases
DK3126381T4 (da) * 2014-04-01 2022-04-04 Biontech Cell&Gene Therapies Gmbh Claudin-6-specifikke immunoreceptorer og t-celleepitoper

Also Published As

Publication number Publication date
JP5889196B2 (ja) 2016-03-22
WO2011057788A1 (en) 2011-05-19
RS60168B1 (sr) 2020-05-29
HK1253300A1 (en) 2019-06-14
MX385874B (es) 2025-03-18
LT3305813T (lt) 2020-05-11
MX2012005444A (es) 2012-06-19
PT3305813T (pt) 2020-04-22
ME02943B (me) 2018-10-20
SI2499161T1 (sl) 2017-12-29
SG10201500975YA (en) 2015-04-29
DK2499161T3 (da) 2017-11-27
EP3305813A1 (en) 2018-04-11
IL218628B (en) 2018-12-31
US11858988B2 (en) 2024-01-02
HUE049404T2 (hu) 2020-09-28
CA2775373C (en) 2019-10-29
US20240092896A1 (en) 2024-03-21
KR101960509B1 (ko) 2019-03-20
AU2010318316B2 (en) 2016-01-14
AU2010318316A1 (en) 2012-04-26
AU2016202235B2 (en) 2017-12-07
IL246710B (en) 2020-05-31
CN111875703B (zh) 2024-06-04
KR20200075903A (ko) 2020-06-26
CN106432500B (zh) 2020-06-02
MX2020011790A (es) 2020-11-24
CA3050655A1 (en) 2011-05-19
CN102741289B (zh) 2016-08-03
HRP20200591T1 (hr) 2020-07-10
AU2018201640A1 (en) 2018-04-05
BR112012011143B1 (pt) 2020-05-19
CY1120300T1 (el) 2019-07-10
EP3689911C0 (en) 2024-08-21
HUE035516T2 (en) 2018-05-28
EP2499161A1 (en) 2012-09-19
RU2675997C2 (ru) 2018-12-25
EP3689911B1 (en) 2024-08-21
KR102317098B1 (ko) 2021-10-25
CN111875703A (zh) 2020-11-03
EP2499161B1 (en) 2017-09-06
JP2017140041A (ja) 2017-08-17
JP2013510808A (ja) 2013-03-28
PT2499161T (pt) 2017-12-05
ES2784483T3 (es) 2020-09-28
ES2649389T3 (es) 2018-01-11
RS56502B1 (sr) 2018-02-28
CN106432500A (zh) 2017-02-22
LT2499161T (lt) 2017-11-27
CN105348389A (zh) 2016-02-24
ES2988907T3 (es) 2024-11-22
JP6502992B2 (ja) 2019-04-17
EP2499161B8 (en) 2017-10-25
NO2499161T3 (OSRAM) 2018-02-03
EP3305813B1 (en) 2020-01-15
IL246710A0 (en) 2016-08-31
US20120308478A1 (en) 2012-12-06
KR20190031335A (ko) 2019-03-25
US9487584B2 (en) 2016-11-08
AU2018201640B2 (en) 2020-04-30
PL3689911T3 (pl) 2024-11-18
NZ734307A (en) 2020-05-29
US20180162938A1 (en) 2018-06-14
CA2775373A1 (en) 2011-05-19
KR102126964B1 (ko) 2020-06-25
MX347150B (es) 2017-04-17
UA128302C2 (uk) 2024-06-05
EP3689911A1 (en) 2020-08-05
SMT201700566T1 (it) 2018-01-11
US10745477B2 (en) 2020-08-18
US20200339677A1 (en) 2020-10-29
UA117799C2 (uk) 2018-10-10
NZ716587A (en) 2017-10-27
ZA201202418B (en) 2013-06-26
US20160222125A1 (en) 2016-08-04
CN102741289A (zh) 2012-10-17
RU2012123995A (ru) 2013-12-20
PL2499161T3 (pl) 2018-03-30
KR20120115226A (ko) 2012-10-17
KR20210130250A (ko) 2021-10-29
HRP20171749T1 (hr) 2018-01-26
SG10202110692WA (en) 2021-12-30
IL218628A0 (en) 2012-05-31
JP6125604B2 (ja) 2017-05-10
PL3305813T3 (pl) 2021-04-19
CN105348389B (zh) 2019-12-20
BR112012011143A2 (pt) 2016-11-29
CY1123192T1 (el) 2021-10-29
EP4461354A2 (en) 2024-11-13
DK3305813T3 (da) 2020-04-20
JP2016047845A (ja) 2016-04-07
EP4461354A3 (en) 2025-03-19
US9932401B2 (en) 2018-04-03

Similar Documents

Publication Publication Date Title
IL246710A0 (en) Antibodies specific for claudin 6 (cldn6)
AU2016202235A1 (en) Antibodies specific for Claudin 6 (CLDN6)
GB0708002D0 (en) Antibodies
SI2200700T1 (sl) Nova protitelesa
IL214996A0 (en) Anti-bcma antibodies
GB0920127D0 (en) Antibodies
LT3023438T (lt) Anti-gitr antikūnai
GB0909906D0 (en) Antibodies
GB0821100D0 (en) Antibodies
IL200437A0 (en) Anti-sclerostin antibodies
EP2427496A4 (en) ANTI-VEGF-D ANTIBODIES
GB0718737D0 (en) Antibodies
GB0702888D0 (en) Novel Antibodies
ZA201006099B (en) Anti-tyrp1 antibodies
GB0920324D0 (en) Antibodies
ZA201007976B (en) Anti-pirb antibodies
EP2499256A4 (en) ANTI-C-MPL ANTIBODIES
GB0818356D0 (en) Antibodies
GB0724185D0 (en) Antibodies
GB0806230D0 (en) Antibodies
GB0823562D0 (en) Antibodies
GB0908945D0 (en) Antibodies